[Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].

We examined efficacy and safety of bevacizumab (BV)+modified FOLFOX6 (mFOLFOX6) regimen for unresectable colorectal cancer. We had 16 patients: liver metastases 8, lung metastases 4, local recurrences 2, and lymph node metastases 2, as for evaluable lesions. The response rate was 46.6%, and disease control rate was 86.6%. Hepatic metastatectomy was done in two cases after PR response. There was 1 infusion related reaction case, 1 tumor bleeding and 1 anal fistula as the adverse events. In conclusion, the BV+mFOLFOX6 is one of the effective and feasible regimens for unresectable colorectal cancer.

[A case of sigmoid colon carcinoma accompanied with hydronephrosis caused by peritoneal dissemination and para-aortic lymph node metastases markedly responded to chemotherapy].

The patient was a 64-year-old male diagnosed as advanced sigmoid colon cancer accompanied with hydronephrosis caused by peritoneal dissemination and para-aortic lymph node metastases. We performed transverse colostomy in the end of June 2008. Though he got renal failure, he was recovered by dialysis and diuretic. He received chemotherapy with LV+5-FU in the middle of August, continuously with bevacizumab (BV)+mFOLFOX6 in the end of October. In December, an elevated CEA marker was decreased after these treatments. Sigmoidectomy was done in the beginning of February 2009, dissemination disappeared completely. Histologically, most mucinous carcinoma cells disappeared or denatured, with viable tumor cells slightly remained.